Blood pressure and end-stage renal disease in men
- PMID: 7494564
- DOI: 10.1056/NEJM199601043340103
Blood pressure and end-stage renal disease in men
Abstract
Background: End-stage renal disease in the United States creates a large burden for both individuals and society as a whole. Efforts to prevent the condition require an understanding of modifiable risk factors.
Methods: We assessed the development of end-stage renal disease through 1990 in 332,544 men, 35 to 57 years of age, who were screened between 1973 and 1975 for entry into the Multiple Risk Factor Intervention Trial (MRFIT). We used data from the national registry for treated end-stage renal disease of the Health Care Financing Administration and from records on death from renal disease from the National Death Index and the Social Security Administration.
Results: During an average of 16 years of follow-up, 814 subjects either died of end-stage renal disease or were treated for that condition (15.6 cases per 100,000 person-years of observation). A strong, graded relation between both systolic and diastolic blood pressure and end-stage renal disease was identified, independent of associations between the disease and age, race, income, use of medication for diabetes mellitus, history of myocardial infarction, serum cholesterol concentration, and cigarette smoking. As compared with men with an optimal level of blood pressure (systolic pressure < 120 mm Hg and diastolic pressure < 80 mm Hg), the relative risk of end-stage renal disease for those with stage 4 hypertension (systolic pressure > or = 210 mm Hg or diastolic pressure > or = 120 mm Hg) was 22.1 (P < 0.001). These relations were not due to end-stage renal disease that occurred soon after screening and, in the 12,866 screened men who entered the MRFIT study, were not changed by taking into account the base-line serum creatinine concentration and urinary protein excretion. The estimated risk of end-stage renal disease associated with elevations of systolic pressure was greater than that linked with elevations of diastolic pressure when both variables were considered together.
Conclusions: Elevations of blood pressure are a strong independent risk factor for end-stage renal disease; interventions to prevent the disease need to emphasize the prevention and control of both high-normal and high blood pressure.
Similar articles
-
Elevated blood pressure and risk of end-stage renal disease in subjects without baseline kidney disease.Arch Intern Med. 2005 Apr 25;165(8):923-8. doi: 10.1001/archinte.165.8.923. Arch Intern Med. 2005. PMID: 15851645
-
Long-term renal function in primary hypertension. An epidemiological and pathophysiological study.Scand J Urol Nephrol Suppl. 1999;199:1-36. Scand J Urol Nephrol Suppl. 1999. PMID: 10349677
-
Prehypertension, obesity, and risk of kidney disease: 20-year follow-up of the HUNT I study in Norway.Am J Kidney Dis. 2009 Oct;54(4):638-46. doi: 10.1053/j.ajkd.2009.03.023. Epub 2009 Jun 10. Am J Kidney Dis. 2009. PMID: 19515474
-
Epidemiology and prevention of blood pressure-related renal disease.J Hypertens Suppl. 1992 Dec;10(7):S77-84. J Hypertens Suppl. 1992. PMID: 1291660 Review.
-
Hypertension-related renal injury: a major contributor to end-stage renal disease.Am J Kidney Dis. 1993 Jul;22(1):164-73. doi: 10.1016/s0272-6386(12)70183-x. Am J Kidney Dis. 1993. PMID: 8322780 Review.
Cited by
-
Effects of Angiotensin II Type 1A Receptor on ACE2, Neprilysin and KIM-1 in Two Kidney One Clip (2K1C) Model of Renovascular Hypertension.Front Pharmacol. 2021 Jan 29;11:602985. doi: 10.3389/fphar.2020.602985. eCollection 2020. Front Pharmacol. 2021. PMID: 33708117 Free PMC article.
-
[Therapeutic strategies to prevent chronic kidney disease progression].Internist (Berl). 2012 Jul;53(7):810-6. doi: 10.1007/s00108-011-3012-3. Internist (Berl). 2012. PMID: 22714581 German.
-
Microalbuminuria and sRAGE in high-risk hypertensive patients treated with nifedipine/telmisartan combination treatment: a substudy of TALENT.Mediators Inflamm. 2012;2012:874149. doi: 10.1155/2012/874149. Epub 2012 Feb 13. Mediators Inflamm. 2012. PMID: 22474401 Free PMC article. Clinical Trial.
-
Hypertension and chronic kidney disease: controversies in pathogenesis and treatment.Minerva Urol Nefrol. 2013 Mar;65(1):37-50. Minerva Urol Nefrol. 2013. PMID: 23538309 Free PMC article. Review.
-
Cost-effectiveness evaluation of a collaborative patient education hypertension intervention in Utah.J Clin Hypertens (Greenwich). 2012 Nov;14(11):760-6. doi: 10.1111/jch.12013. Epub 2012 Oct 3. J Clin Hypertens (Greenwich). 2012. PMID: 23126347 Free PMC article.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials